Anzeige
Mehr »
Login
Sonntag, 23.06.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Kursrakete startet...: Jetzt einsteigen und von außergewöhnlichem Potenzial profitieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QE9Y | ISIN: US1856341029 | Ticker-Symbol: 84C
Tradegate
21.06.24
15:20 Uhr
0,356 Euro
-0,010
-2,73 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CLENE INC Chart 1 Jahr
5-Tage-Chart
CLENE INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,3560,37621.06.

Aktuelle News zur CLENE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrClene Inc.: Clene Presents Preliminary Data for CNM-Au8 as a Potential Treatment for Rett Syndrome158CNM-Au8 demonstrated neuroprotective effects in an in vitro model of Rett Syndrome, a rare pediatric neurodevelopmental diseaseCNM-Au8 also demonstrated rescue of mitochondrial deficits in induced...
► Artikel lesen
DiAnalyst Scoreboard: 5 Ratings For Clene1
DiClene Inc.: Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting42Survival analyses with CNM-Au8 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baseline (hazard ratio: 0.431, p=0.0002)Average of 28% NfL reduction...
► Artikel lesen
DiClene Inc. - 8-K, Current Report1
06.06.Clene Inc. - S-8, Securities to be offered to employees in employee benefit plans1
05.06.Clene Inc.: Clene to Present at the Emerging Growth Conference3
28.05.Clene Inc.: Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)2
23.05.Analyst Scoreboard: 6 Ratings For Clene2
14.05.Clene Inc.: Clene to Present at Upcoming May Conferences4
10.05.Clene Inc. reports results for the quarter ended in March - Earnings Summary1
08.05.Clene Inc.: Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights313Data from long-term extension of Phase 2 VISIONARY-MS clinical trial of CNM-Au8® demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original...
► Artikel lesen
08.05.Clene Inc. - 8-K, Current Report1
08.05.Clene Inc. - 10-Q, Quarterly Report1
26.04.Clene Inc. - 8-K, Current Report2
17.04.The Analyst Verdict: Clene In The Eyes Of 5 Experts1
16.04.Clene stock rallies 52% post-market on MS drug data2
16.04.Clene Inc.: Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting2
09.04.Clene Inc. - 8-K, Current Report2
15.03.Clene Inc.: Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®2
13.03.Breaking Down Clene: 4 Analysts Share Their Views1
Seite:  Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1